HCW Biologics is developing immunotherapies that target cellular senescence to mitigate the effects of inflammaging, a key contributor to age-related diseases. By disrupting this link, the company aims to extend healthspan and improve overall quality of life for aging populations.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Aging is often accompanied by a chronic, low-grade inflammation known as inflammaging, which contributes to the development of various age-related diseases and reduces overall healthspan. Current treatments often address individual diseases associated with aging but fail to target the underlying inflammatory processes driving these conditions. This leaves a significant unmet need for therapies that can broadly mitigate the effects of inflammaging.
Solution
HCW Biologics is developing a new class of immunotherapies designed to disrupt inflammaging by targeting cellular senescence, a key driver of chronic inflammation. Their approach aims to restore immune homeostasis and reduce the production of pro-inflammatory cytokines, thereby addressing the root cause of many age-related diseases. By modulating the immune system's response to senescent cells, HCW Biologics' therapies have the potential to prevent or delay the onset of multiple age-related conditions, extending healthspan and improving the quality of life for aging populations. The company's pipeline focuses on addressing chronic inflammation and its downstream effects on various organ systems.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related diseases driven by chronic inflammation, as well as healthcare providers seeking innovative therapies to extend patient healthspan.
Features
- Development of novel immunotherapies targeting cellular senescence
- Modulation of the immune system to reduce pro-inflammatory cytokine production
- Focus on addressing the underlying causes of inflammaging
- Pipeline of therapies targeting chronic inflammation and age-related diseases